Industry News
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Annual SoCalBio Investor & Partnering Conference in Newport Beach, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at SCDM in Baltimore. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin, Christopher Kata and Nick Travers…
Read More
How TrialStat’s Quarterly Releases Deliver Real Value to Sponsors, CROs, and Sites In today’s fast-paced clinical research environment, flexibility and responsiveness aren’t just nice-to-haves-they’re mission-critical. At TrialStat, our commitment to quarterly platform releases is rooted in one goal: to empower our clients with a nimble, innovative, and responsive technology ecosystem that grows with their needs.…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG CRO Summit in Amsterdam. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin and Nick…
Read MoreExcerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–The results of COMFORT 2, the second Nalu Medical Peripheral Nerve Stimulation (PNS) RCT, were published on July 30th, 2025, in the peer-reviewed journal Chronic Pain & Management and are available here. These results confirm the positive clinical outcomes from the COMFORT trial, the first Nalu PNS RCT,…
Read More
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 Excerpt from the Press Release: DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE)…
Read More
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study Excerpt from the Press Release: MENLO PARK, Calif., June 18, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from…
Read More
Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care Excerpt from the Press Release: DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and…
Read More
BP1.15205 is a potentially best-in-class OX2R agonist being investigated in narcolepsy and other central disorders of hypersomnolence A first-in-human study is planned to start in 2H 2025; topline clinical data is anticipated in 2026 Excerpt from the Press Release: PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced successful dosing of the first participants in its Phase 1 trial of CPTX2309, Capstan’s lead anti-CD19 in vivo CAR-T candidate, for the…
Read More